LEADER 03422nam 22005774a 450 001 9910144142503321 005 20230617005329.0 010 $a1-281-32237-7 010 $a9786611322373 010 $a0-470-75150-9 010 $a0-470-75149-5 035 $a(CKB)1000000000536040 035 $a(EBL)351646 035 $a(OCoLC)476173140 035 $a(SSID)ssj0000266801 035 $a(PQKBManifestationID)11226110 035 $a(PQKBTitleCode)TC0000266801 035 $a(PQKBWorkID)10305044 035 $a(PQKB)11624785 035 $a(MiAaPQ)EBC351646 035 $a(Au-PeEL)EBL351646 035 $a(CaPaEBR)ebr10233014 035 $a(CaONFJC)MIL132237 035 $a(EXLCZ)991000000000536040 100 $a20050324d2005 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aVascular complications of diabetes$b[electronic resource] $ecurrent issues in pathogenesis and treatment /$feditor, Richard Donnelly ; associate editor, Edward Horton 205 $a2nd ed. 210 $aMalden, Mass. $cBlackwell Pub.$d2005 215 $a1 online resource (242 p.) 300 $aDescription based upon print version of record. 311 $a1-4051-2785-6 320 $aIncludes bibliographical references and index. 327 $aThe public health impact of the diabetes epidemic -- Risk factors -- Diabetic nephropathy -- Coronary heart disease and diabetes -- Diabetes and cerebrovascular disease -- Erectile dysfunction -- Evidence-based interventions to prevent or retard vascular complications -- Classification and clinical features of neuropathy -- Pathophsiology [sic] of diabetic neuropathy -- Epidemiology and natural history of DPN -- Detections/screenings/assessment -- Foot ulceration and charcot arthropathy -- Treatment options -- Management guidelines for diabetic peripheral neuropathy and foot ulceration -- Diabetic retinopathy: epidemiology and risk factors -- Classification and diagnosis of diabetic retinopathy -- Diabetic maculopathy -- Proliferative diabetic retinopathy -- Non-retinal diabetic ocular complications -- Pathophysiology & potential targets for therapeutic intervention -- Protein kinase C -- PKC activation & vascular permeability -- Role of PKC activation in cardiovascular and renal complications of diabetes -- Experimental pharmacology using isoform-selective PKC inhibitors -- Clinical trials with ruboxistaurin. 330 $aDiabetes has reached epidemic proportions, and the cardiovascular complications of diabetes are life-threatening and disabling. This book is unique in providing a simple explanation of the biochemical role of PKC in diabetes complications, which allows clinicians to understand why PKC inhibitors (in development) are an exciting prospect for future treatment to slow progression of eye & foot complications. New features of this Second Edition include:Updated throughout to reflect the impact of recent major clinical trials on current clinical practice Include 606 $aDiabetic angiopathies 615 0$aDiabetic angiopathies. 676 $a616.1/3 701 $aDonnelly$b Richard$f1960-$0224728 701 $aHorton$b Edward S$0864981 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910144142503321 996 $aVascular complications of diabetes$91930548 997 $aUNINA